报价延迟最少15分钟:2025/08/25 16:58 EDT
盘后时段
|
||||
|
0.3167 
|
|
|
常规时段
|
|
|
|
|
||||||||||||
|
|
|
|
|
0.3167
|
|
|
| 价值评估 |
|
盈利(现时/预测)
-1.15/-0.45
|
|
企业价值
11.99M
|
| 资产负债 |
|
每股账面净值
1.14
|
| 现金流量 |
|
现金流量率
--
|
| 损益表 |
|
收益
6.81M
|
|
每股收益
0.22
|
|
同行比较
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
报价延迟最少15分钟：2025/08/25 16:58 EDT
同行比较之报价最少15分钟延迟
|
业务概览
|
|||
| Co-Diagnostics Inc is a molecular diagnostics company. It develops, licenses, and commercializes molecular technologies such as lab systems (MDx device) and manufacture and sell reagents used for tests that are designed using the detectionand/or analysis of nucleic acid molecules (DNA or RNA). CDI's low-cost system uses its tests to diagnose tuberculosis, Zika, hepatitis B and C, Malaria, dengue and HIV.The Company's technologies are utilized for tests that are designed using the detection and/or analysis of nucleic acid molecules (DNA or RNA). The Company also uses its proprietary technology to design specific tests for its Co-Dx PCR platform and to locate genetic markers for use in applications other than infectious diseases. |
